Mental or Behavioral Dysfunction
Novo’s GLP-1 Liraglutide May Protect Brain from Alzheimer’s, New Study Finds
GLP-1, Liraglutide, Alzheimer’s Disease, Brain Protection, Cognitive Decline, Novo Nordisk
Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results
Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option
Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment
Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment
Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar
Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
FDA Advisory Panel Rejects Lykos’ MDMA Treatment for PTSD Despite Promising Results
MDMA, PTSD, FDA, Lykos Therapeutics, Psychopharmacologic Drugs Advisory Committee, psychedelic therapy
Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment
Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment